Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy

Ye Won Jeon; Seung Taek Lim; HongKi Gwak; Seon Young Park; 서영진

추천

검색

자료유형: 학술저널

저자정보: Ye Won Jeon (Department of Surgery The Catholic University St. Vincent’s Hospital Suwon Korea) Seung Taek Lim (Department of Surgery The Catholic University St. Vincent’s Hospital Suwon Korea) HongKi Gwak (Department of Surgery The Catholic University St. Vincent’s Hospital Suwon Korea) Seon Young Park (Department of Surgery The Catholic University St. Vincent's Hospital Suwon Korea) 서영진 (가톨릭대학교)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.23 No.5

발행연도: 2020.1

수록면: 521 - 532 (12page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: The regimen including concurrent docetaxel, doxorubicin, and cyclophosphamide (TAC) has been categorized as an important risk factor for febrile neutropenia (FN). This comparative study examined the clinical impact of long-acting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim) during adjuvant TAC chemotherapy in Korean patients with advanced breast cancer. Methods: We analyzed data from 239 patients who received 6 cycles of adjuvant TAC chemotherapy. We categorized patients into 2 groups according to the use of primary prophylactic pegfilgrastim and compared the incidence and risk of FN, hospital care costs, and survival in the 2 groups. Results: The incidence of FN decreased from 54.2% to 21.2% in all patients, after the use of pegfilgrastim. The analysis of a total of 1,432 chemotherapy cycles showed that the incidence of FN decreased from 36.1% to 9.1% after the use of pegfilgrastim. Moreover, the decrease in the incidence of FN with the use of pegfilgrastim resulted in a significant decrease in the mean duration of neutropenia (4.15 to 1.29 days), the risk of hospitalization (99.5% to 29.7%) and the mean total hospital care cost (USD 3,038 to USD 2,347). High relative dose intensity (RDI) in patients treated with pegfilgrastim than in those not treated with pegfilgrastim (99.18% vs. 93.85%) was associated with a better overall survival (p = 0.033). Conclusions: The use of pegfilgrastim during adjuvant TAC chemotherapy was significantly associated with a decrease in the incidence and risk of FN, hospital care costs, and risk of death compared to the use of adjuvant TAC without primary prophylaxis.

#Breast neoplasms #Drug therapy #Febrile neutropenia #Granulocyte colony-stimulating factor

참고문헌 (27)

참고문헌 신청

Dale DC / 2002 / Colony-stimulating factors for the management of neutropenia in cancer patients / Drugs 62(Suppl 1):1~15

Kuderer NM / 2007 / Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy : a systematic review / J Clin Oncol 25:3158~3167

Kuderer NM / 2006 / Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients / Cancer 106:2258~2266

Schilling MB / 2011 / Costs and outcomes associated with hospitalized cancer patients with neutropenic complications : a retrospective study / Exp Ther Med 2:859~866

Lalami Y / 2017 / Impact of chemotherapy-induced neutropenia(CIN)and febrile neutropenia(FN)on cancer treatment outcomes : an overview about well-established and recently emerging clinical data / Crit Rev Oncol Hematol 120:163~179

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!